In summary, the HDAC6-selective inhibitor could overcome the BTZ resistance via inhibition of cell survival signaling and the STAT3–NF-κB–LMP2 pathway in BTZ-resistant MM. This evidence concerns the gene NFKB1 and Miyoshi myopathy.